New drug combo aims to boost survival in aggressive leukemia
NCT ID NCT07651163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests three different chemotherapy regimens in 450 young adults (ages 15-65) with intermediate- or high-risk acute myeloid leukemia (AML). All regimens include the experimental drug lisaftoclax plus standard chemotherapies. The main goal is to see which combination leads to the highest 2-year survival rate. Participants are randomly assigned to one of three treatment groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lisaftoclax combined with standard chemotherapy drugs (daunorubicin, cytarabine, homoharringtonine, aclarubicin)
- What this could lead to
- If successful, this could point toward a more effective chemotherapy regimen for young adults with aggressive AML, potentially improving long-term survival.
- What could go wrong
- This is an early-to-mid-stage trial with 450 participants, so results may not apply to all patients. Chemotherapy side effects like infection and organ damage are significant risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Can a new drug combo outperform standard care for a tough blood cancer?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- New drug cocktail aims to stop leukemia return after transplant